<DOC>
	<DOCNO>NCT00424268</DOCNO>
	<brief_summary>The aim study compare efficacy roflumilast placebo pulmonary function symptomatic parameter patient chronic obstructive pulmonary disease ( COPD ) concomitant administration tiotropium . The study duration last 28 week . The study provide data safety tolerability roflumilast .</brief_summary>
	<brief_title>Effect Roflumilast Chronic Obstructive Pulmonary Disease ( COPD ) Patients Treated With Tiotropium : The HELIOS Study ( BY217/M2-128 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Main History COPD least 12 month prior baseline visit chronic productive cough 3 month 2 year prior baseline visit FEV1/FVC ratio ( postbronchodilator ) ≤ 70 % FEV1 ( postbronchodilator ) ≥ 40 % ≤ 70 % predict Treated tiotropium least 3 month enrollment At least 28 puff rescue medication last week prior randomization Main COPD exacerbation indicate treatment systemic glucocorticosteroids and/or antibiotic stop least 4 week prior baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Roflumilast</keyword>
</DOC>